Screener
BridgeBio Pharma BBIO Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $29,058 | $36,228 |
| Accrued compensation and benefits | 39,338 | 76,703 |
| Accrued research and development liabilities | 54,430 | 41,436 |
| Operating lease liabilities, current portion | 4,439 | 6,192 |
| Deferred revenue, current portion | 6,115 | 7,190 |
| 2027 Notes, net | 547,483 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's accrued expenses?
- BridgeBio Pharma (BBIO) reported accrued expenses of $39.34M in Q1 2026.
- How has BridgeBio Pharma's accrued expenses changed year-over-year?
- BridgeBio Pharma's accrued expenses increased by 17.6% year-over-year, from $33.45M to $39.34M.
- What is the long-term trend for BridgeBio Pharma's accrued expenses?
- Over 5 years (2020 to 2025), BridgeBio Pharma's accrued expenses has grown at a 20.9% compound annual growth rate (CAGR), from $29.68M to $76.7M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about BridgeBio Pharma's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude